Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Issue 4 (12th April 2017)

• Record Type: Journal Article
• Authors: Sam, C.; Desai, P.; Laber, D.; Patel, A.; Visweshwar, N.; Jaglal, M.
• Is Part Of: Transfusion medicine. Volume 27:Issue 4(2017:Aug.)
• Page Start: 300
• Page End: 302
• Publication Date: 2017-04-12
• Subjects: blood substitute -- plasma exchange -- TTP; Blood -- Transfusion -- Periodicals; 615.39
• DOI: 10.1111/tme.12407
• Languages: English
• ISSNs: 0958-7578

Abstract

SUMMARY: Objective: To determine if pegylated bovine carboxyhaemoglobin can be utilised in a thrombotic thrombocytopenic purpura (TTP) patient. Background: TTP is a condition characterized by thrombotic microangiopathy and has a high mortality rate when left untreated. Therapeutic plasma exchange is well established as the most effective and evidence‐based treatment of TTP. Methods: The ability to administer plasma exchange therapy is limited in Jehovah's Witnesses who decline blood products due to religious beliefs. Pegylated bovine carboxyhaemoglobin is a novel oxygen transfer agent in development for the management of complications of ischaemia due to acute anaemia. Results: Treatment was well tolerated, with grade 1 paresthesia of the right face and arm 1 h after the first infusion of Sanguinate, which spontaneously resolved and did not recur, and grade 1 cardiac troponin elevation after receiving the medication (with peak at 0·079 ng mL −1 ), but further workup with electrocardiogram and echocardiogram was unremarkable. By discharge on day 19, the patient's haemoglobin increased to 8·8 g dL −1 and platelet count to 221 000. Conclusions: We report the first case of TTP in a Jehovah's Witness that was successfully managed with the use of pegylated bovine carboxyhaemoglobin as an adjunct medication.